Endpoints News 28. Jan. 2026 Boehringer Ingelheim takes rare kidney disease drug to Phase 3 despite puzzling mid-stage data
Endpoints News 27. Jan. 2026 CMS picks Lilly’s Trulicity, Gilead's Biktarvy for third round of Medicare negotiations
Endpoints News 27. Jan. 2026 Insilico’s latest deal is a $120M cardiometabolic drug discovery pact with Qilu Pharma
Endpoints News 26. Jan. 2026 Sarepta touts three-year Duchenne gene therapy data after patient deaths
Endpoints News 26. Jan. 2026 Genyro licences DNA builder from Caltech; Dizal targets Hong Kong listing